Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma
In: Leukemia Research, Jg. 111 (2021-12-01), S. 106705-106705
Online
unknown
Zugriff:
Peripheral T-cell lymphoma (PTCL) is characterized by an aggressive clinical behavior. Chidamide has been approved for the treatment of relapsed/refractory (R/R) PTCL in China. We compared the efficacy of chidamide-contained regimens with chemotherapy (ChT) in R/R PTCL. Based on the second-line treatments, patients were divided into three groups, including ChT, ChT combined with chidamide (chidamide + ChT) and chidamide combined with or without other targeted agents (targeted therapy) group. Chidamide + ChT group had a better progression-free survival (PFS) compared with targeted therapy group (p = 0.013), and showed a trend towards superior PFS compared with ChT group (p = 0.079). Among patients with high second-line International Prognostic Index (IPI) (3-5), chidamide+ChT group had a longer PFS than ChT group(p = 0.018), and PFS in targeted therapy group was not inferior to that in chidamide+ChT group (p = 0.200). Among patients younger than 60 years, chidamide+ChT group demonstrated a PFS benefit over targeted therapy group (p = 0.010). Among CD30-negative patients, PFS was superior in the chidamide+ChT group compared with ChT group (p0.001). Conversely, results observed above were absent in patients with low second-line IPI or patients older than 60 years or CD30-positive patients. Overall, the combination of chidamide and ChT may be an effective treatment strategy for R/R PTCL.
Titel: |
Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma
|
---|---|
Autor/in / Beteiligte Person: | Cai, Jun ; Huang, Huiqiang ; Cai, Qingqing ; Wang, Jin-Ni ; Zhang, Yuchen ; Fang, Yu ; Liu, Panpan ; Ma, Shuyun ; Su, Ning ; Huang, He ; Zhi Ming Li ; Tian, Xiaopeng ; Xia, Yi |
Link: | |
Zeitschrift: | Leukemia Research, Jg. 111 (2021-12-01), S. 106705-106705 |
Veröffentlichung: | Elsevier BV, 2021 |
Medientyp: | unknown |
ISSN: | 0145-2126 (print) |
DOI: | 10.1016/j.leukres.2021.106705 |
Schlagwort: |
|
Sonstiges: |
|